WO2008092117A3 - Immunoglobulins with modifications in the fcr binding region - Google Patents

Immunoglobulins with modifications in the fcr binding region Download PDF

Info

Publication number
WO2008092117A3
WO2008092117A3 PCT/US2008/052113 US2008052113W WO2008092117A3 WO 2008092117 A3 WO2008092117 A3 WO 2008092117A3 US 2008052113 W US2008052113 W US 2008052113W WO 2008092117 A3 WO2008092117 A3 WO 2008092117A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulins
modifications
binding region
fcr binding
variant
Prior art date
Application number
PCT/US2008/052113
Other languages
French (fr)
Other versions
WO2008092117A2 (en
Inventor
Gregory Alan Lazar
Sher Bahadur Karki
Original Assignee
Xencor Inc
Gregory Alan Lazar
Sher Bahadur Karki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc, Gregory Alan Lazar, Sher Bahadur Karki filed Critical Xencor Inc
Publication of WO2008092117A2 publication Critical patent/WO2008092117A2/en
Publication of WO2008092117A3 publication Critical patent/WO2008092117A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
PCT/US2008/052113 2007-01-25 2008-01-25 Immunoglobulins with modifications in the fcr binding region WO2008092117A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88663507P 2007-01-25 2007-01-25
US60/886,635 2007-01-25

Publications (2)

Publication Number Publication Date
WO2008092117A2 WO2008092117A2 (en) 2008-07-31
WO2008092117A3 true WO2008092117A3 (en) 2008-12-31

Family

ID=39645209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/052113 WO2008092117A2 (en) 2007-01-25 2008-01-25 Immunoglobulins with modifications in the fcr binding region

Country Status (1)

Country Link
WO (1) WO2008092117A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI671403B (en) 2005-03-31 2019-09-11 中外製藥股份有限公司 Method for controlling controlled assembly of polypeptide
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2007114325A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
MX369784B (en) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Method of modifying isoelectric point of antibody via amino acid substitution in cdr.
PH12018501459A1 (en) 2007-09-26 2019-11-11 Chugai Pharmaceutical Co Ltd Modified antibody constant region
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
JP5787446B2 (en) 2009-03-19 2015-09-30 中外製薬株式会社 Antibody constant region variants
AR076875A1 (en) 2009-05-15 2011-07-13 Chugai Pharmaceutical Co Ltd ANTIBODY AGAINST TYPEOSIN KINASE RECEIVER (ANTI-AXL)
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP5889181B2 (en) 2010-03-04 2016-03-22 中外製薬株式会社 Antibody constant region variants
TWI667346B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
MX339809B (en) 2010-05-27 2016-06-09 Merck Sharp & Dohme Corp * Method for preparing antibodies having improved properties.
CN108715614A (en) 2010-11-30 2018-10-30 中外制药株式会社 The antigen binding molecules combined are repeated with polymolecular antigen
WO2012133782A1 (en) 2011-03-30 2012-10-04 中外製薬株式会社 Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
BR112013021526B1 (en) 2011-02-25 2021-09-21 Chugai Seiyaku Kabushiki Kaisha VARIANT POLYPEPTIDE, METHODS FOR MAINTAINING OR DECREASE BINDING ACTIVITIES TO FCGRIIA (TYPE R) AND FCGRIIA (TYPE H) AND INCREASING FCGRIIB BINDING ACTIVITY OF A POLYPEPTIDE AND FOR SUPPRESSING THE PRODUCTION OF AN ANTIBODY AGAINST A POLYENDENDOPEPTIDE ANTIBODY FC, METHODS FOR THE PRODUCTION OF SUCH POLYPEPTIDE WITH MAINTAINED OR DECREASED AND INCREASED BINDING ACTIVITIES AND FOR THE SUPPRESSED PRODUCTION OF AN ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF A POLYPEPTIDE
US20140127240A1 (en) 2011-04-21 2014-05-08 Bayer Pharma Aktiengesellschaft Novel Binder-Drug Conjugates (ADCs) and Use of Same
JP6322411B2 (en) 2011-09-30 2018-05-09 中外製薬株式会社 Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
MX366968B (en) 2011-09-30 2019-08-01 Chugai Pharmaceutical Co Ltd Antigen-binding molecule inducing immune response to target antigen.
US10024867B2 (en) 2011-09-30 2018-07-17 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
TW201817745A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
WO2013047752A1 (en) 2011-09-30 2013-04-04 中外製薬株式会社 Antigen-binding molecule for promoting loss of antigens
BR112014013081A2 (en) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha drug-containing cell vehicle for formation of an immune complex
TWI593705B (en) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
US20160046693A1 (en) 2012-02-24 2016-02-18 Chugai Seiyaku Kabushiki Kaisha Antigen-Binding Molecule for Promoting Disappearance of Antigen via Fc gamma RIIB
JP6280031B2 (en) 2012-03-29 2018-02-14 中外製薬株式会社 Anti-LAMP5 antibody and use thereof
ES2856272T3 (en) 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule to remove aggregated antigens
RU2743463C2 (en) * 2012-05-30 2021-02-18 Чугаи Сейяку Кабусики Кайся Antigen-binding molecule specific to target tissue
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
CA2882272C (en) 2012-08-24 2023-08-29 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc region variant
TWI693073B (en) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients
EP3557260B1 (en) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
BR112015032414A2 (en) 2013-06-24 2017-11-07 Chugai Pharmaceutical Co Ltd therapeutic agent comprising humanized antiepyrregulin antibody as active ingredient for non-small cell lung carcinoma excluding adenocarcinoma
RU2758952C1 (en) 2013-09-27 2021-11-03 Чугаи Сейяку Кабусики Кайся Method for producing a polypeptide heteromultimer
EP3763813A1 (en) 2013-12-04 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
PT3086814T (en) 2013-12-23 2020-09-04 Bayer Pharma AG Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US11760807B2 (en) 2014-05-08 2023-09-19 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
JP6227191B1 (en) 2014-12-19 2017-11-08 中外製薬株式会社 Anti-myostatin antibody, polypeptide comprising mutant Fc region, and method of use
KR102605798B1 (en) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
TWI805046B (en) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Use of IL-6 receptor antibody for preparing pharmaceutical composition
WO2016159213A1 (en) 2015-04-01 2016-10-06 中外製薬株式会社 Method for producing polypeptide hetero-oligomer
ES2784603T3 (en) 2015-06-02 2020-09-29 Novo Nordisk As Insulins with recombinant polar extensions
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
TWI751300B (en) 2015-09-18 2022-01-01 日商中外製藥股份有限公司 Il-8-binding antibodies and uses thereof
MA43348A (en) 2015-10-01 2018-08-08 Novo Nordisk As PROTEIN CONJUGATES
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
CA3008678A1 (en) 2015-12-21 2017-06-29 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
JP7141336B2 (en) 2015-12-25 2022-09-22 中外製薬株式会社 Anti-myostatin antibodies and methods of use
KR20180091918A (en) 2015-12-28 2018-08-16 추가이 세이야쿠 가부시키가이샤 A method for efficiently purifying the Fc region-containing polypeptide
EP3400023A1 (en) * 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
EP4112641A1 (en) 2016-03-15 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
JP7251981B2 (en) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト Prodrugs of Cytotoxic Active Agents with Enzymatic Cleavage Groups
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
WO2017181152A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
JP6527643B2 (en) 2016-08-05 2019-06-05 中外製薬株式会社 Composition for treating or preventing IL-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018079997A1 (en) 2016-10-27 2018-05-03 국민대학교 산학협력단 Aglycosylated antibody fc region for treating cancer
JP7030811B2 (en) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Specific antibody with KSP inhibitor-drug conjugate (ADC)
EP3558388A1 (en) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) having enzymatically cleavable groups
WO2018114798A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
AU2018235838B2 (en) 2017-03-16 2023-12-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
KR20240039221A (en) 2017-03-16 2024-03-26 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l1 variant immunomodulatory proteins and uses thereof
AU2018235835A1 (en) 2017-03-16 2019-09-05 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
EP3601333A4 (en) * 2017-03-28 2021-05-26 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
US11471537B2 (en) 2017-04-05 2022-10-18 Novo Nordisk A/S Oligomer extended insulin-Fc conjugates
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
EP4218813A3 (en) 2017-07-27 2023-08-16 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
JP7382922B2 (en) 2017-09-20 2023-11-17 中外製薬株式会社 Dosing regimen for combination therapy using PD-1 system binding antagonists and GPC3 targeting agents
CA3077509A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
US20200283500A1 (en) 2017-10-18 2020-09-10 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
SG11202009010RA (en) 2018-03-15 2020-10-29 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CN112566938A (en) 2018-06-03 2021-03-26 拉姆卡普生物测试有限公司 Bispecific antibodies against CEACAM5 and CD47
US20210363219A1 (en) 2018-06-15 2021-11-25 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
US20220177587A1 (en) 2018-09-19 2022-06-09 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
KR20210135987A (en) 2018-11-30 2021-11-16 알파인 이뮨 사이언시즈, 인코포레이티드 CD86 variant immunomodulatory protein and uses thereof
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
TW202102544A (en) * 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 Bispecific antibody
CA3136816A1 (en) 2019-04-17 2020-10-22 Alpine Immune Sciences, Inc. Methods and uses of variant icos ligand (icosl) fusion proteins
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
KR20220113791A (en) 2019-12-18 2022-08-16 에프. 호프만-라 로슈 아게 Bispecific anti-CCL2 antibody
JP2023525032A (en) 2020-05-08 2023-06-14 アルパイン イミューン サイエンシズ インコーポレイテッド APRIL and BAFF inhibitory immunomodulatory proteins, with and without T-cell inhibitory proteins, and methods of use thereof
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
EP4204447A1 (en) 2020-08-28 2023-07-05 Sana Biotechnology, Inc. Modified anti-viral binding agents
IL301701A (en) 2020-12-18 2023-05-01 Lamkap Bio Beta Ag Bispecific antiodies against ceacam5 and cd47
IL308336A (en) 2021-05-07 2024-01-01 Alpine Immune Sciences Inc Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
EP4355775A1 (en) 2021-06-18 2024-04-24 F. Hoffmann-La Roche AG Bispecific anti-ccl2 antibodies
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047350A2 (en) * 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047350A2 (en) * 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARMOUR K L ET AL: "Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities.", EUROPEAN JOURNAL OF IMMUNOLOGY AUG 1999, vol. 29, no. 8, August 1999 (1999-08-01), pages 2613 - 2624, XP002501617, ISSN: 0014-2980 *
ARMOUR KATHRYN L ET AL: "Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies.", MOLECULAR IMMUNOLOGY DEC 2003, vol. 40, no. 9, December 2003 (2003-12-01), pages 585 - 593, XP002501618, ISSN: 0161-5890 *
CANFIELD S M ET AL: "THE BINDING AFFINITY OF HUMAN IGG FOR ITS HIGH AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO ACIDS IN THE C-H2 DOMAIN AND IS MODULATED BY THE HINGE REGION", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, vol. 173, no. 6, 1 January 1991 (1991-01-01), pages 1483 - 1492, XP002278409, ISSN: 0022-1007 *
MORGAN A ET AL: "THE N-TERMINAL END OF THE CH2 DOMAIN OF CHIMERIC HUMAN IGG1 ANTI-HLA-DR IS NECESSARY FOR C1Q, FCGAMMARI AND FCGAMMARIII BINDING", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 86, no. 2, 1 October 1995 (1995-10-01), pages 319 - 324, XP001106372, ISSN: 0019-2805 *
RADAEV SERGEI ET AL: "Recognition of immunoglobulins by Fcgamma receptors.", MOLECULAR IMMUNOLOGY MAY 2002, vol. 38, no. 14, May 2002 (2002-05-01), pages 1073 - 1083, XP002489882, ISSN: 0161-5890 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies

Also Published As

Publication number Publication date
WO2008092117A2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
WO2008092117A3 (en) Immunoglobulins with modifications in the fcr binding region
WO2010106180A3 (en) Optimized fc variants
PH12016500081A1 (en) Immunoglobulin variants and uses thereof
WO2008143954A3 (en) Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2009067636A3 (en) Modified insulin polypeptides and their uses
WO2007041635A3 (en) Fc variants with optimized fc receptor binding properties
WO2006105062A3 (en) Altered antibody fc regions and uses thereof
EP2033248A4 (en) Bonded fuel cell assembly, methods, systems and sealant compositions for producing the same
WO2009058492A3 (en) Fc variants with altered binding to fcrn
EP4269443A3 (en) Fc variants with altered binding to fcrn
WO2012142515A3 (en) Fc fusion proteins comprising novel linkers or arrangements
WO2009022154A3 (en) Peptide with multiple epitopes
WO2012175751A3 (en) Fc variants with reduced effector functions
WO2014144791A3 (en) Therapeutic peptides
WO2007109254A3 (en) Stabilized polypeptide compositions
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
WO2010065969A8 (en) Sparc binding scfcs
EP2808393A3 (en) Fucosylation-deficient cells
WO2007101698A3 (en) Modified molecules which promote hematopoiesis
WO2009106553A3 (en) Lipolytic enzyme variant with improved stability and polynucleotides encoding same
MX2010007716A (en) COMBINATION OF AN ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART.
WO2010057882A3 (en) Composition for producing anti-amyloid beta peptide antibodies with d-peptides
WO2007067433A3 (en) Poly(trimethylene terephthalate)/poly(alpha-hydroxy acid) films
WO2009135482A3 (en) Bearing module

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08728336

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08728336

Country of ref document: EP

Kind code of ref document: A2